To Verify the Efficacy and Safety of Rapamycin Coated Peripheral Balloon Catheter in the Treatment of Femoral Popliteal Artery Disease

Not Applicable

Not yet recruiting

• Conditions: Peripheral Arterial Disease

• Registration Number: NCT05662618
• Lead Sponsor: Shanghai Bomaian Medical Technology Co., Ltd

Brief Summary

A prospective randomized trial to validate the efficacy and safety of rapamycin coated peripheral balloon catheter in the treatment of femoral popliteal artery disease.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-12
• Study First Submitted: 2022-12-01
• Study First Submitted QC: 2022-12-14
• Last Update Submitted: 2022-12-14
• Study First Posted: 2022-12-22
• Last Update Posted: 2022-12-22
• Study Start: 2022-12-31
• Primary Completion: 2025-06-30
• Study Completion: 2025-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 276

Inclusion Criteria

• Patients with arteriosclerosis obliterans of lower extremities, and Rutherford's rating is 2-5.
• Patients with severe stenosis (≥ 70%) or occlusion of superficial femoral artery and/or proximal popliteal artery (within P1 stage)
• Patients with total length of target lesion ≤ 20cm and length of occluded segment ≤ 15cm (the distance between two segments of lesions less than 2cm is considered as the same lesion)
• Those who agree to participate in this clinical trial and sign the informed consent form Exclusion criteria：
• This operation is planned to intervene patients with bilateral lower limbs.
• Patients whose guide wire fails to pass through the target lesion.
• Patients whose target lesion is in stent restenosis (ISR).
• ≥ 2 lesions need to be treated in the target vessel (if the distance between two lesions is less than 2cm, it is considered as the same lesion).
• Patients with target lesions requiring rotary resection/laser therapy/thrombus aspiration for this treatment.
• Patients with ipsilateral iliac artery inflow tract lesions that cannot be successfully treated (i.e. residual stenosis ≥ 30% after treatment).
• There is less than one unobstructed blood vessel under the knee of the target limb before operation (unobstructed is defined as visual stenosis<50%).
• Residual stenosis ≥ 30% after pre expansion of target lesion or severe (≥ Grade D) flow limiting dissection.
• Patients with obviously abnormal renal function (creatinine > 2.5mg/dL or 220umol/L) or undergoing dialysis.
• Patients with severe liver dysfunction who are judged by the researcher to be unsuitable for surgery.
• Patients with severe coagulation dysfunction or uncontrolled severe infection who are not suitable for surgery.
• Patients who have performed distal amputation (above metatarsal) on the affected or opposite limb in the past.
• Patients who received local or systemic thrombolytic therapy within 48 hours before surgery.
• Patients receiving vascular interventional therapy or surgical treatment on target limb within 30 days before operation.
• Patients known to be allergic to aspirin, clopidogrel, paclitaxel and rapamycin.
• Pregnant or lactating women and patients with family planning during the study
• Patients who are participating in clinical trials of other drugs or medical devices but are not included in the group.
• Patients with life expectancy less than 12 months
• Patients not suitable for this study.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
primary patency rate, PPR.	12months	It is defined as:Primary patency of target lesion: the target lesion is patency (systolic peak blood flow ratio\<2.4) and there is no clinically driven target lesion revascularization (TLR) by Doppler ultrasound.

Secondary Outcome Measures

Name	Time	Method
Device success rate	The day of operation.	It is defined as: the balloon catheter can reach the target lesion, expand successfully, without rupture, and withdraw successfully.
Operation success rate	1DAY	The success of surgery was defined as: residual stenosis ≤ 50% (without salvage stent implantation) or ≤ 30% (with salvage stent implantation).
Target Lesion Revascularization incidence.	12 months after operation.	Target Lesion Revascularization is defined as any re intervention treatment required in the target lesion.

Trial Locations

Locations (1)

The First Medical Center of the General Hospital of the Chinese People's Liberation Army; 🇨🇳 Beijing, Beijing, China